CASSAVA SCIENCES INC.

Cassava Sciences Reports Q3 2024 Financial and Operating Results

07 Nov 2024 06:55:00 By Nasdaq GlobeNewswire

Cassava Sciences to Report Third Quarter 2024 Results on November 7, 2024

31 Oct 2024 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Resolves SEC Investigation

26 Sep 2024 17:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

24 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Names Rick Barry as Chief Executive Officer

09 Sep 2024 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences to Present at the H.C. Wainwright Global Investment Conference

03 Sep 2024 07:31:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Q2 2024 Financial Results and Operational Updates

08 Aug 2024 07:00:01 By Nasdaq GlobeNewswire

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

05 Aug 2024 08:01:00 By Nasdaq GlobeNewswire

Cassava Sciences to Hold Conference Call to Discuss Recent Developments and Provide a Company Update on Thursday, August 8, 2024 at 8:30 am ET

01 Aug 2024 07:30:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Expansion of Open-Label Extension Trials

30 Jul 2024 07:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Changes in Executive Leadership, Enhanced Corporate Governance and Other Initiatives

17 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Cassava Sciences Issues Statement on Former Science Advisor

28 Jun 2024 14:58:09 By Nasdaq GlobeNewswire

Cassava Sciences Reports Q1 2024 Financial Results and Clinical Updates on Phase 3 Trials of Simufilam

10 May 2024 15:02:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Over $125 Million Raised from Warrant Distribution

08 May 2024 10:00:00 By Nasdaq GlobeNewswire

Tomorrow is Last Day to Trade SAVAW Warrants on NASDAQ

01 May 2024 08:10:00 By Nasdaq GlobeNewswire

Redemption Date Announced for Warrants

15 Apr 2024 08:20:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Completion of an Interim Safety Review of Oral Simufilam On-going Phase 3 Trials

25 Mar 2024 08:13:00 By Nasdaq GlobeNewswire

Cassava Sciences Announces Virtual Presentation at the AD/PD™ 2024 International Conference

04 Mar 2024 08:15:00 By Nasdaq GlobeNewswire

Cassava Sciences Reports Full-year 2023 Financial Results and Corporate Updates

28 Feb 2024 08:14:00 By Nasdaq GlobeNewswire

No Decline in Cognition Scores in Patients with Mild Alzheimer's Disease Who Received Simufilam Continuously For 24 Months

07 Feb 2024 08:08:00 By Nasdaq GlobeNewswire